News

Childhood-onset Sjögren’s disease can cause lasting damage to the body’s organs by early adulthood, regardless of how active the disease has been or how severely the symptoms have manifested. Those are the findings of a single-center study in the U.K. that investigated the “long-term disease trajectories and complications of…

Note: This story was updated Dec. 17, 2025, to correct that the infiltrations were done in the parotid glands, not the parathyroid. A minimally invasive treatment that involves irrigating the major salivary glands with corticosteroids, a type of anti-inflammatory medication, significantly reduced both objective and subjective measures of dry mouth…

Four genes involved in a form of cell death called pyroptosis are highly active in people with Sjögren’s disease and may serve as disease biomarkers or therapeutic targets, a study reports. By examining the activity of each of the genes — PECAM1, IFI16, AIM2, and MPEG1 —the researchers…

A new artificial intelligence (AI) tool has demonstrated the ability to significantly enhance the diagnosis of Sjögren’s disease by rapidly and accurately analyzing tissue samples, according to a multicenter European study. The AI system achieved an accuracy of more than 87% in classifying the focus score, which is the…

The severity of fatigue experienced by people with Sjögren’s disease affects their pain severity, and also has an impact on the effect of external factors, such as weather changes and loud noises, that can amplify a patient’s pain. That’s according to the findings of a single-center study in Italy,…

Two global Phase 3 clinical trials are now testing dazodalibep, Amgen’s experimental therapy for Sjögren’s disease, in two groups of adults. One of the studies is still recruiting participants. One of the trials, called HZNP-DAZ-301 (NCT06104124), has completed enrollment of 651 people with moderate-to-severe systemic (body-wide) Sjögren’s…

People with Sjögren’s disease who received the experimental therapy ianalumab (VAY736) in Phase 3 clinical trials reported greater reductions in disease activity than those given a placebo within two months of starting treatment. That’s according to new data ianalumab’s developer, Novartis, shared at the American College of Rheumatology…

Sjögren’s disease patients found significant relief from debilitating symptoms like dryness, pain, and fatigue after treatment with Johnson & Johnson’s investigational antibody, nipocalimab, in a Phase 2 clinical trial. Full results from the study, dubbed DAHLIAS (NCT04969812), confirmed that nipocalimab treatment, compared to a placebo, not only…

An experimental therapy from Ouro Medicines is being tested in a Phase 1b clinical trial on people who have Sjögren’s disease or idiopathic inflammatory myopathy (IMM), another autoimmune condition. “This study reflects Ouro’s strategy of expanding OM336 development to additional immune-mediated diseases where an ‘immune reset’ approach would…

The investigational therapy telitacicept leads to significant and clinically meaningful reductions in disease activity and patient-reported symptoms among adults with primary Sjögren’s disease, according to new data from a Phase 3 clinical trial conducted in China. The findings — consistent with Phase 2 trial data — were…